The Pharma Closeout

The Pharma Closeout — Long-history pharma/biotech business-development deal database with a proprietary two-axis grading layer. Deal records span the early 1990s to 2026 and carry: announcement date, both counterparties, deal structure class (LICENSE / CO-DEV / ASSET / M&A / TAKE-PRIV), disclosed total value, therapeutic area, lead assets, deal status, plus the vendor's own scores — a Critic Score (deal-day market sentiment, built from announcement-week coverage in at least four independent sources) and an Outcome Score (how the deal actually aged, graded five years post-close on strategic ra…

The Pharma Closeout offers (Alternative, Fundamental, Sentiment) — Deal records in the low thousands, with counts rising across pages captured at different dates: 1,500+ published records, a 2,378-deal database cited in the Hype Gap methodology, and 3,424 deals indexed totalling $5.53 trillion disclosed deal value on the library index — with 899 to ~900 records carrying a post-close Outcome Score. Per record: both parties, structure, disclosed value, therapeutic area, lead assets, two scores and a tiered source list. The 899 scored deals are the scarce subset.

BD comparable-transaction benchmarking (structure, headline value, milestone norms by therapeutic area and counterparty type); acquirer track-record scoring for diligence on a bidder's historical execution; event-driven and merger-arbitrage research using the Hype Gap as a learned prior that Street deal-day verdicts are frequently wrong (43.2% of graded deals diverge by 25+ points); licence-pricing and deal-terms calibration; corpus of labelled outcome pairs (announcement sentiment versus realised outcome) for training deal-success or M&A-abuse prediction models; corporate-development strategy study of how consolidation waves aged

Coverage spans US, UK, Other, China/HK, Japan, Europe; Pharmaceuticals, Financial Exchanges & Data; alternative, fundamental, sentiment; equities.